Diabetes remission after bariatric surgery is characterized by high glycemic variability and high oxidative stress

Nutr Metab Cardiovasc Dis. 2017 Nov;27(11):949-955. doi: 10.1016/j.numecd.2017.07.004. Epub 2017 Jul 18.

Abstract

Background and aim: To evaluate glycemic variability (GV) and oxidative stress in patients who achieved type 2 diabetes (T2DM) remission after bariatric surgery (BS).

Methods and results: Twenty-two patients (M/F10/12, age 50 ± 9 years, BMI 31 ± 6 kg/m2) who were in remission of T2DM (T2DM remitters) after BS since at least 1 year and 22 age-, sex- and BMI-matched control subjects were studied. Of the BS group, eleven subjects had undergone Roux-en-Y gastric bypass (RYGB) and eleven subjects sleeve gastrectomy (SG). Oral glucose tolerance test (OGTT), 7 days-continuous glucose monitoring, 24-h urinary excretion of 8-isoprostaglandin F2α (8-isoPGF2α) and dietary intake evaluation were performed. According to general linear model for repeated measures, glucose and insulin response during OGTT were significantly different in T2DM remitter than in control subjects (p < 0.001, for both). All measures of GV (standard deviation, coefficient of variation and mean amplitude of glucose excursions) were significantly higher in T2DM remitters than in controls, (p < 0.001 for all). These indexes were higher among RYGB than SG patients (p < 0.05). The time spent out of the 60-160 mg/dl range was significantly longer in T2DM remitters undergoing RYGB than in controls (p < 0.02). Mean 24-h urinary 8-isoPGF2α excretion was significantly higher in T2DM remitters than that of control subjects (p = 0.04). All GV indexes were directly correlated with blood glucose levels at 30 and 60 min during OGTT (p < 0.05-0.001).

Conclusion: Remission of T2DM after BS is characterized by high GV and high oxidative stress in the face of fasting blood glucose and HbA1c within the normal range.

Keywords: Bariatric surgery; Diabetes remission; Glycemic variability; Oxidative stress.

MeSH terms

  • Adult
  • Biomarkers / blood
  • Biomarkers / urine
  • Blood Glucose / metabolism*
  • Case-Control Studies
  • Chi-Square Distribution
  • Diabetes Mellitus, Type 2 / blood*
  • Diabetes Mellitus, Type 2 / diagnosis
  • Diabetes Mellitus, Type 2 / etiology
  • Dinoprost / analogs & derivatives
  • Dinoprost / urine
  • Energy Intake
  • Female
  • Gastrectomy*
  • Gastric Bypass*
  • Glycated Hemoglobin / metabolism
  • Humans
  • Insulin / blood
  • Linear Models
  • Male
  • Middle Aged
  • Obesity / complications
  • Obesity / diagnosis
  • Obesity / surgery*
  • Oxidative Stress*
  • Remission Induction
  • Time Factors
  • Treatment Outcome

Substances

  • Biomarkers
  • Blood Glucose
  • Glycated Hemoglobin A
  • Insulin
  • hemoglobin A1c protein, human
  • 8-epi-prostaglandin F2alpha
  • Dinoprost